Krystal Biotech Inc (KRYS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Krystal Biotech Inc (KRYS) has a cash flow conversion efficiency ratio of 0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($39.66 Million) by net assets ($1.14 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Krystal Biotech Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Krystal Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read KRYS liabilities breakdown for a breakdown of total debt and financial obligations.
Krystal Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Krystal Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sasol Ltd
JSE:SOL
|
0.155x |
|
Hoshine Silicon Ind Co Ltd
SHG:603260
|
0.006x |
|
Shanghai Fosun Pharmaceutical Group Co Ltd
SHG:600196
|
0.038x |
|
Beacon Roofing Supply Inc
NASDAQ:BECN
|
-0.070x |
|
AXIS Capital Holdings Ltd
NYSE:AXS
|
0.106x |
|
Compañía de Minas Buenaventura S.A.A
F:MBU
|
0.052x |
|
Lumen Technologies Inc
NYSE:LUMN
|
-0.503x |
|
Ford Otomotiv Sanayi AS
IS:FROTO
|
0.212x |
Annual Cash Flow Conversion Efficiency for Krystal Biotech Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Krystal Biotech Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Krystal Biotech Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $946.38 Million | $123.42 Million | 0.130x | +214.35% |
| 2023-12-31 | $778.64 Million | $-88.80 Million | -0.114x | +40.78% |
| 2022-12-31 | $522.23 Million | $-100.57 Million | -0.193x | -138.45% |
| 2021-12-31 | $593.58 Million | $-47.94 Million | -0.081x | +9.56% |
| 2020-12-31 | $292.08 Million | $-26.08 Million | -0.089x | +3.17% |
| 2019-12-31 | $202.91 Million | $-18.71 Million | -0.092x | -10.55% |
| 2018-12-31 | $113.23 Million | $-9.45 Million | -0.083x | -6.09% |
| 2017-12-31 | $49.47 Million | $-3.89 Million | -0.079x | +98.27% |
| 2016-12-31 | $289.00K | $-1.31 Million | -4.536x | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical tr… Read more